431 related articles for article (PubMed ID: 10623666)
21. Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma.
Dunlap J; Le C; Shukla A; Patterson J; Presnell A; Heinrich MC; Corless CL; Troxell ML
Breast Cancer Res Treat; 2010 Apr; 120(2):409-18. PubMed ID: 19418217
[TBL] [Abstract][Full Text] [Related]
22. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
23. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident.
Yamamoto S; Romanenko A; Wei M; Masuda C; Zaparin W; Vinnichenko W; Vozianov A; Lee CC; Morimura K; Wanibuchi H; Tada M; Fukushima S
Cancer Res; 1999 Aug; 59(15):3606-9. PubMed ID: 10446970
[TBL] [Abstract][Full Text] [Related]
24. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
25. In microdissected ductal carcinoma in situ, HER-2/neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology.
Ho GH; Calvano JE; Bisogna M; Borgen PI; Rosen PP; Tan LK; Van Zee KJ
Cancer; 2000 Dec; 89(11):2153-60. PubMed ID: 11147584
[TBL] [Abstract][Full Text] [Related]
26. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
27. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
Shin SJ; Simpson PT; Da Silva L; Jayanthan J; Reid L; Lakhani SR; Rosen PP
Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
[TBL] [Abstract][Full Text] [Related]
28. Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
Keohavong P; Gao WM; Mady HH; Kanbour-Shakir A; Melhem MF
Cancer Lett; 2004 Aug; 212(1):121-30. PubMed ID: 15246568
[TBL] [Abstract][Full Text] [Related]
29. Sebaceous carcinoma. Tumor progression through mutational inactivation of p53.
Gonzalez-Fernandez F; Kaltreider SA; Patnaik BD; Retief JD; Bao Y; Newman S; Stoler MH; Levine PA
Ophthalmology; 1998 Mar; 105(3):497-506. PubMed ID: 9499782
[TBL] [Abstract][Full Text] [Related]
30. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ.
De Leeuw WJ; Berx G; Vos CB; Peterse JL; Van de Vijver MJ; Litvinov S; Van Roy F; Cornelisse CJ; Cleton-Jansen AM
J Pathol; 1997 Dec; 183(4):404-11. PubMed ID: 9496256
[TBL] [Abstract][Full Text] [Related]
31. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer.
Bhargava V; Thor A; Deng G; Ljung BM; Moore DH; Waldman F; Benz C; Goodson W; Mayall B; Chew K
Mod Pathol; 1994 Apr; 7(3):361-8. PubMed ID: 8058709
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression.
Carvalho I; Milanezi F; Martins A; Reis RM; Schmitt F
Breast Cancer Res; 2005; 7(5):R788-95. PubMed ID: 16168125
[TBL] [Abstract][Full Text] [Related]
33. Disparate E-cadherin mutations in LCIS and associated invasive breast carcinomas.
Rieger-Christ KM; Pezza JA; Dugan JM; Braasch JW; Hughes KS; Summerhayes IC
Mol Pathol; 2001 Apr; 54(2):91-7. PubMed ID: 11322170
[TBL] [Abstract][Full Text] [Related]
34. Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections.
Chen T; Dhingra K; Sahin A; Sneige N; Hortobagyi G; Aldaz CM
Breast Cancer Res Treat; 1996; 39(2):177-85. PubMed ID: 8872326
[TBL] [Abstract][Full Text] [Related]
35. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.
Tolbert DM; Noffsinger AE; Miller MA; DeVoe GW; Stemmermann GN; Macdonald JS; Fenoglio-Preiser CM
Mod Pathol; 1999 Jan; 12(1):54-60. PubMed ID: 9950163
[TBL] [Abstract][Full Text] [Related]
36. Protein expression of c-erbB-2 and p53 in normal ducts, ductal carcinoma in situ and invasive carcinoma of the same breast.
Menezes MV; Cestari AL; Almeida O; Alvarenga M; Pinto GA; Gurgel MS; Souza GA; Zeferino LC
Sao Paulo Med J; 2006 May; 124(3):121-4. PubMed ID: 17119686
[TBL] [Abstract][Full Text] [Related]
37. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH
J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462
[TBL] [Abstract][Full Text] [Related]
38. Mutations of p53 gene in breast cancer in the Egyptian province of Dakahliya.
El-Ghannam DM; Arafa M; Badrawy T
J Oncol Pharm Pract; 2011 Jun; 17(2):119-24. PubMed ID: 20015931
[TBL] [Abstract][Full Text] [Related]
39. Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions.
Shi ST; Yang GY; Wang LD; Xue Z; Feng B; Ding W; Xing EP; Yang CS
Carcinogenesis; 1999 Apr; 20(4):591-7. PubMed ID: 10223186
[TBL] [Abstract][Full Text] [Related]
40. Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas.
Robanus-Maandag EC; Bosch CA; Kristel PM; Hart AA; Faneyte IF; Nederlof PM; Peterse JL; van de Vijver MJ
J Pathol; 2003 Sep; 201(1):75-82. PubMed ID: 12950019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
